• In the case of DIA CN the docking results

  2023-04-17

  

  In the case of DIA-4CN the docking results do not show any interaction between the iron atom and the inhibitor, presumably due to the reduced ability to form a complex involving the -CONN- moiety versus the bidentate -CONHNH- central group of HYD-4Me. This results in a considerable gap between the i

• br Methods for antifungal testing

  2023-04-17

  

  Methods for antifungal testing of mucorales species The Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methods currently in place for in vitro antifungal susceptibility testing of filamentous fungi [8], [9] have

• br Obstructing SNARE zippering Sharma et al demonstrated for

  2023-04-14

  

  Obstructing SNARE “zippering” Sharma et al. demonstrated for the first time that in the postmortem AD brains, the level of SNARE complex formation, which is necessary for driving synaptic vesicle fusion at the presynaptic active zone, is significantly reduced [123]. In the absence of changes in e

• Analysis of the enzyme activity expressed as rate of product

  2023-04-14

  

  Analysis of the enzyme activity, expressed as rate of product formation per unit serum volume (20μl), between the diagnostic groups revealed that ApB activity was significantly decreased in the patient group both at recruitment and after 13months when the substrate concentration used was 1.5mM (pthe

• br Development of lorlatinib from crizotinib to a clinical

  2023-04-14

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• Cells have developed strategies aiming to

  2023-04-14

  

  Cells have developed strategies aiming to enhance both the efficiency of proteins with chaperone activity as well as their overall antioxidant capacity to maintain proteostasis under oxidative stress conditions (Miyata et al., 2012). For instance, 2-Cys peroxiredoxin is an abundantly expressed, anti

• Preclinical models indicate roles for adiponectin in

  2023-04-14

  

  Preclinical models indicate roles for adiponectin in the maintenance of hepatic lipid metabolism. Adiponectin overexpression prevents accumulation of triglycerides or the deleterious lipid metabolites diacylglycerols or ceramides [5,8]. Direct manipulation of adiponectin expression demonstrates a po

• Lonidamine br Introduction Clinical manifestations of Alzhei

  2023-04-14

  

  Introduction Clinical manifestations of Alzheimer's disease (AD) are mainly characterized by progressive intellectual deterioration, memory impairment, cognitive impairment, and psychiatric symptoms. The pathogenesis of AD remains unclear, mainly containing genetic factors, neurotransmitter disor

• ACK can be localized to clathrin coated

  2023-04-14

  

  ACK1 can be localized to clathrin-coated vesicles [1]. The association of SNX9 with synaptojanin-1 would suggest the two cooperate during endocytosis at the synapse by coupling the sorting nexin to changes in phospholipid composition. ACK1 in turn negatively regulates the association of SNX9 with ta

• Both subcutaneous s c and mucosal administration

  2023-04-14

  

  Both subcutaneous (s.c.) and mucosal administration of short synthetic peptide derivatives of AChR prevent the onset of EAMG, but do not treat ongoing EAMG [80], [81], [82], [83], [84], [85]. The selection of peptides for treatment is mainly based on the identification of immunodominant T- and B-cel

• An AXL decoy receptor with enhanced GAS binding properties M

  2023-04-14

  

  An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer cysteine protease and a murine breast cancer cell line in grafting assays

• Sodium Phenylbutyrate APP is a member of a conserved protein

  2023-04-13

  

  APP is a member of a conserved protein family that also includes amyloid precursor-like proteins 1 and 2 (APLP1, APLP2).8, 9, 10 The proteins in this family are type I single-pass transmembrane Sodium Phenylbutyrate with receptor-like structural features but not entirely clear cellular functions.11

• In a recent issue of

  2023-04-13

  

  In a recent issue of , Minokoshi and colleagues have added more light to our understanding of the role of hypothalamic AMPK in the regulation of energy balance. Previous seminal work from the same group suggested that AMPK in the PVH might be involved in the modulation of feeding . Here, they show

• Another important finding of our study is the observation th

  2023-04-13

  

  Another important finding of our study is the observation that high glucose per se does not affect TER in mature HREC monolayers; but at the same time it does upregulate ICAM-1 directly and activates HRECs to leukocyte adhesion. This would imply that high glucose affects TER in mature HREC monolayer

• 10-Hydroxycamptothecin The only psychostimulant treatment op

  2023-04-12

  

  The only psychostimulant treatment option in Turkey is methylphenidate (Çetin et al., 2015). It is broken down by carboxylase enzyme (CES1) (Sun et al., 2004). From the point of pharmacokinetics, it may be suggested that CES1 gene polymorphisms may be the key responsible factors in patients resistan

16048 records 343/1070 page Previous Next First page 上5页 341342343344345 下5页 Last page